麻醉期间应用FloTrac/Vigileo监测液体治疗对胶质瘤开颅切除术患者预后的影响  

The Effects of Fluid Therapy with Flo Trac/Vigileo Monitoring during Anesthesia for Glioma Resection Patients' Prognosis

作　　者：邓靖单 张岳农[1] 廖亿粦[1] 

机构地区：[1]广东省梅州市人民医院,广东梅州514000

出　　处：《中国医学创新》2015年第13期65-67,共3页Medical Innovation of China

摘　　要：目的:探讨研究麻醉期间应用FloTrac/Vigileo监测液体治疗对胶质瘤开颅切除术患者预后的影响。方法:随机选择本院60例择期进行胶质瘤开颅切除术患者作为研究对象,采用随机数字表法进行分组,试验组30例患者麻醉期间选用FloTrac/Vigileo监测液体治疗,对照组30例患者采用常规液体治疗方法,比较两组患者经过治疗的预后效果。结果:术后24 h后(T6)试验组患者心指数(4.44±1.21)L/(min·m2),明显高于常规对照组患者(3.89±1.01)L/(min·m2),比较差异有统计学意义(P<0.05)。两组患者经过治疗后,试验组患者监护室停留时间(15.43±4.54)h和住院时间(15.56±4.12)d均明显少于对照组患者监护室停留时间(20.68±5.31)h和住院时间(19.22±4.35)d,比较差异有统计学意义(P<0.05)。结论:麻醉期间应用FloTrac/Vigileo监测进行液体治疗对胶质瘤患者可有效提高心指数,明显缩短其在监护室的停留时间和住院时间,促进患者的恢复,值得在临床上推广应用。Objective：To evaluate the effect of fluid therapy with FloTrac/Vigileo monitoring during anesthesia for glioma resection patients’ prognosis. Method：60 patients undergoing elective glioma craniotomy were randomly divided into 2 groups（n=30）：experimental group（group E）and control group（group C）. During anesthesia,the patients in the group E received goal-directed fluid therapy with FloTrac/Vigileo monitoring,while the patients in the group C were given the conventional liquid treatment,and the patients’ prognosis of the two groups were compared. Result：The cardiac index in postoperative 24 h（T6）of the group E was（4.44±1.21）L/（min·m2）,which was higher than that of the group C（3.89±1.01）L/（min·m2）. After treatment,the patients’ duration of stay in ICU was（15.43±4.54）h and duration of hospital（15.56±4.12）d in the group E,which was significantly less than that of the group C,which were（20.68±5.31）h and（19.22±4.35）d（P〈0.05）. Conclusion：The fluid therapy with FloTrac/Vigileo monitoringduring anesthesia for glioma resection patient can effectively improve the cardiac index,and maintain the stability of hemodynamics,and shorten the patients’ duration of stay in ICU and duration of hospital,which is deserved to promote.

关 键 词：麻醉 FloTrac/Vigileo监测 液体治疗 胶质瘤 

分 类 号：R614[医药卫生—麻醉学] R739.41[医药卫生—外科学]